+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Targeted Oncology Therapeutics: Therapeutics, Markets, Players and Forecasts

  • ID: 5004007
  • Report
  • February 2020
  • Region: Global
  • Greystone Associates
1 of 3

A number of factors are changing the way market participants view the cancer therapeutics market. These factors are evident in the disease targets and drug classes that comprise a significant number of recent trials. After decades of disappointment and missed financial objectives, the genetic underpinnings of disease are converging with improved computer-assisted pharmacological decision making. Market sector participants now find themselves pursuing realistic therapeutic strategies that have the potential to fulfill product strategies in both scientific and human terms.

What You Will Learn

  • What is the market share of approved therapeutics?
  • What is the global supply picture for targeted therapeutics?
  • Who are the market leaders, by Indication? by Product?
  • What is the therapeutic coverage across all oncology indications? What are the product opportunities?
  • What are the established products in this space? by target, indication, API class, revenue?
  • What is the competitive picture for the major Oncology market segments?   
    • Drug treatment resources
    • Competitive therapy map
    • Clinical trial activity
  • Who are the leading competitors in the field of next-generation therapeutics?
Note: Product cover images may vary from those shown
2 of 3
  1. Executive Summary
  2. The Recombinant Drug Ecosystem
  3. Targeted Oncology Therapeutics Market Leaders
  4. Oncology Biologics – Competitive Considerations
  5. Approved Drugs for targeted Oncology Therapeutics
  6. FDA-approved Drugs
  7. EMA-approved Drugs
  8. Biosimilars of Trastuzumab
  9. EMA Approved Biosimilars
  10. The Impact of Litigation on Biosimilar Product Launches
  11. Target Oncology Therapeutics – Market Segments
  12. Breast Cancers
  13. Colorectal Cancers
  14. Hematology Cancers
  15. Lung Cancers
  16. Melanomas
  17. Metastatic Gastric Cancers
  18. Neurological Cancers
  19. Renal Cell Carcinomas
  20. Urothelial Cancers
  21. Supplier Competitive Assessments

Charts, Tables, Graphs, and Visualizations

  • Approved mAbs - Market Share by Product Activity
    • Global Supplier Activity Map
    • Targeted Oncology Market Leaders (Indications, Products)
    • FDA/EMA Approved Product Market Coverage by Supplier
  • Established Products (Baseline & Commercialization Summaries)
    • Adcetris (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Avastin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Blincyto (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Cyramza (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Adcetris (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Darzalex (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Empliciti (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Erbitux (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Gazyva (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Herceptin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Imfinzi (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Keytruda (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Opdivo (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Perjeta (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Rituxan (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Tecentriq (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Vectibix (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Yervoy (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
    • Zevalin (Detailed Profiles, Indications, Dosage Form, Historical Revenue, Revenue Forecast)
  • Emerging Products
    • Arzerra (Detailed Profiles, Indications, Supply Chain)
    • Bavencio (Detailed Profiles, Indications, Supply Chain)
    • Besponsa (Detailed Profiles, Indications, Supply Chain)
    • Enhertu (Detailed Profiles, Indications, Supply Chain)
    • Herzuma (Detailed Profiles, Indications, Supply Chain)
    • Kadcyla (Detailed Profiles, Indications, Supply Chain)
    • Kanjinti (Detailed Profiles, Indications, Supply Chain)
    • Lartruvo (Detailed Profiles, Indications, Supply Chain)
    • Libtayo (Detailed Profiles, Indications, Supply Chain)
    • Lumoxiti (Detailed Profiles, Indications, Supply Chain)
    • Mvasi (Detailed Profiles, Indications, Supply Chain)
    • Ogivri (Detailed Profiles, Indications, Supply Chain)
    • Omtruzant (Detailed Profiles, Indications, Supply Chain)
    • Padcev (Detailed Profiles, Indications, Supply Chain)
    • Polivy (Detailed Profiles, Indications, Supply Chain)
    • Portrazza (Detailed Profiles, Indications, Supply Chain)
    • Poteligeo (Detailed Profiles, Indications, Supply Chain)
    • Ruxience (Detailed Profiles, Indications, Supply Chain)
    • Truxima (Detailed Profiles, Indications, Supply Chain)
    • Unituxin (Detailed Profiles, Indications, Supply Chain)
    • Zirabev (Detailed Profiles, Indications, Supply Chain)
    • EMA Approved Biosimilars, All
    • EMA, Approved Biosimilars for Oncology Incications
    • Biosimilars, Patent Litigation Impact Map
  • Targeted Oncology Market Assessments
    • Breast Cancer - Drug Treatment Resource Map, by Type
    • Breast Cancer – Competitive Therapy Map, Total Revenue by Year
    • Breast Cancer – Clinical Trial Activity, Sponsor/Collaborator
    • Breast Cancer – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Breast Cancer – Clinical Trial Activity by Trial Phase
    • Colorectal Cancer - Drug Treatment Resource Map, by Type
    • Colorectal Cancer – Competitive Therapy Map, Total Revenue by Year
    • Colorectal Cancer – Clinical Trial Activity, Sponsor/Collaborator
    • Colorectal Cancer – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Colorectal Cancer – Clinical Trial Activity by Trial Phase
    • Hematology Cancers - Drug Treatment Resource Map, by Type
    • Hematology Cancers – Competitive Therapy Map, Total Revenue by Year
    • Hematology Cancers – Clinical Trial Activity, Sponsor/Collaborator
    • Hematology Cancers – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Hematology Cancers– Clinical Trial Activity by Trial Phase
    • Lung Cancers - Drug Treatment Resource Map, by Type
    • Lung Cancers – Competitive Therapy Map, Total Revenue by Year
    • Lung Cancers – Clinical Trial Activity, Sponsor/Collaborator
    • Lung Cancers – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Lung Cancers– Clinical Trial Activity by Trial Phase
    • Melanomas - Drug Treatment Resource Map, by Type
    • Melanomas – Competitive Therapy Map, Total Revenue by Year
    • Melanomas – Clinical Trial Activity, Sponsor/Collaborator
    • Melanomas – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Melanomas– Clinical Trial Activity by Trial Phase
    • Metastatic Gastric Cancers - Drug Treatment Resource Map, by Type
    • Metastatic Gastric Cancers – Competitive Therapy Map, Total Revenue by Year
    • Metastatic Gastric Cancers – Clinical Trial Activity, Sponsor/Collaborator
    • Metastatic Gastric Cancers – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Metastatic Gastric Cancers– Clinical Trial Activity by Trial Phase
    • Neurological Cancers - Drug Treatment Resource Map, by Type
    • Neurological Cancers – Competitive Therapy Map, Total Revenue by Year
    • Neurological Cancers – Clinical Trial Activity, Sponsor/Collaborator
    • Neurological Cancers – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Neurological Cancers– Clinical Trial Activity by Trial Phase
    • Renal Cell Carcinomas - Drug Treatment Resource Map, by Type
    • Renal Cell Carcinomas – Competitive Therapy Map, Total Revenue by Year
    • Renal Cell Carcinomas – Clinical Trial Activity, Sponsor/Collaborator
    • Renal Cell Carcinomas – Clinical Trial Activity, First-listed Interventional Therapeutic
    • Renal Cell Carcinomas– Clinical Trial Activity by Trial Phase
    • Urothelial Cancers - Drug Treatment Resource Map, by Type
    • Urothelial Cancers – Competitive Therapy Map, Total Revenue by Year
  • Supplier Competitive Assessments
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

Adroll
adroll